Bluejay Diagnostics, Inc. (BJDX) intrinsic value & 10-year financials
Bluejay Diagnostics, Inc. (BJDX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.74
- Market cap
- $334.3K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -416.1%
- Free cash flow (FY2025)
- -$6.2M
BJDX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$6.8M | -$15.25 | -$6.2M | — | -575.4% |
| FY2024 | — | -$7.7M | -$114.19 | -$8.1M | — | -634.2% |
| FY2023 | — | -$10.0M | -$9.08 | -$9.0M | — | -749.9% |
| FY2022 | $249.0K | -$9.3M | -$0.46 | -$8.9M | -3741.5% | -526.4% |
| FY2021 | — | -$3.5M | -$0.41 | -$4.4M | — | -43.1% |
| FY2020 | — | -$1.2M | — | — | — | 32.5% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Bluejay Diagnostics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Bluejay Diagnostics, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.9% ROIC.
Bluejay Diagnostics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Bluejay Diagnostics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.